Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Sevelamer Hydrochloride). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Inophos helps lower phosphorus levels in the blood of patients with end-stage renal disease (ESRD).
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Sevelamer's recommended starting dose for patients not already taking a phosphate binder is 800 to 1600 mg, given as two to four 400 mg Sevelamer tablets with meals, based on the serum phosphorus level. The recommendation for Renophos 400 in patients with hyperphosphatemia is given below. Starting dose of Renophos for dialysis patients not taking any phosphate binder: for serum phosphorus above 5.5 and below 7.5 mg/dL, 800 mg (2 tablets) three times daily with meals; for serum phosphorus 7.5 up to 9.0 mg/dL, 1200 mg (3 tablets) three times daily with meals; for serum phosphorus 9.0 mg/dL or above, 1600 mg (4 tablets) three times daily with meals. Starting dose for dialysis patients switching from calcium acetate to Sevelamer: calcium acetate 667 mg (1 tablet) corresponds to Sevelamer 800 mg (2 tablets); calcium acetate 1334 mg (2 tablets) corresponds to Sevelamer 1200 mg (3 tablets); calcium acetate 2001 mg (3 tablets) corresponds to Sevelamer 2000 mg (5 tablets). Dose titration guideline: if serum phosphorus is above 5.5 mg/dL, increase the dose by 400 mg (1 tablet) per meal at two week intervals; if serum phosphorus is between 3.5 and 5.5 mg/dL, maintain the current dose; if serum phosphorus is below 3.5 mg/dL, decrease the dose by 400 mg (1 tablet) per meal. Dose titration for all patients taking Sevelamer: the dosage should be adjusted based on the serum phosphorus concentration, with a goal of lowering serum phosphorus to 5.5 mg/dL or less. The dose may be increased or decreased by one tablet per meal at two week intervals as necessary.
Side Effects
Inophos may cause dyspepsia, peritonitis, diarrhea, nausea, constipation, itching, abdominal bloating, vomiting, fatigue, loss of appetite and joint pain, and less commonly ileus, bowel obstruction and bowel perforation.
Cautions & Contraindications
Warnings & Precautions
Safety and effectiveness data for Inophos have not yet been established in patients with dysphagia, other swallowing difficulties, severe gastrointestinal motility disorders (including severe constipation), or a history of major GI tract surgery. Inophos should therefore be used with caution in patients with these conditions.
Contraindications
Sevelamer hydrochloride should not be used in patients with low blood phosphate levels (hypophosphatemia) or in those with a bowel obstruction. It is also contraindicated in anyone with a known hypersensitivity to sevelamer hydrochloride or to any of the other ingredients it contains.